Showing results (1271-1280 of 31,365) with videos related to
Sort By:
Pageof 3,137
Journal of Medicinal Chemistry|March 4, 2005
Identification of small molecule chemical inhibitors of the collagen-specific chaperone Hsp47Christy A Thomson, Helen M Atkinson, Vettai S AnanthanarayananJournal of Medicinal Chemistry|June 12, 1992
Synthesis and thromboxane A2/prostaglandin H2 receptor antagonistic activity of phenol derivativesS Fukumoto, M Shiraishi, Z Terashita, et al.Journal of Medicinal Chemistry|May 15, 1992
3-(2-Carboxyindol-3-yl)propionic acid-based antagonists of the N-methyl-D-aspartic acid receptor associated glycine binding siteF G Salituro, B L Harrison, B M Baron, et al.Journal of Medicinal Chemistry|September 3, 2004
In vitro cytotoxic activities of 2-alkyl-4,6-diheteroalkyl-1,3,5-triazines: new molecules in anticancer researchRita Menicagli, Simona Samaritani, Giovanni Signore, et al.Journal of Medicinal Chemistry|September 3, 2004
Indolebutylamines as selective 5-HT(1A) agonistsTimo Heinrich, Henning Böttcher, Gerd D Bartoszyk, et al.Journal of Medicinal Chemistry|June 26, 1992
Conformational analysis of dopamine D-2 receptor antagonists of the benzamide series in relation to a recently proposed D-2 receptor-interaction modelI Pettersson, T LiljeforsJournal of Medicinal Chemistry|February 7, 1992
A study on the contribution of the 1-phenyl substituent to the molecular electrostatic potentials of some benzazepines in relation to selective dopamine D-1 receptor activityI Pettersson, K Gundertofte, J Palm, et al.Journal of Medicinal Chemistry|August 20, 2004
DNA binding ligands with improved in vitro and in vivo potency against drug-resistant Staphylococcus aureusWenhao Hu, Roland W Bürli, Jacob A Kaizerman, et al.Journal of Medicinal Chemistry|August 20, 2004
Synthesis of novel rhinacanthins and related anticancer naphthoquinone estersNgampong Kongkathip, Suwaporn Luangkamin, Boonsong Kongkathip, et al.Journal of Medicinal Chemistry|August 20, 2004
Pharmacological exploitation of the alpha1-adrenoreceptor antagonist doxazosin to develop a novel class of antitumor agents that block intracellular protein kinase B/Akt activationYeng-Jeng Shaw, Ya-Ting Yang, Jason B Garrison, et al.Pageof 3,137